PRCT Stock Analysis: Procept Biorobotics | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 1.142m USD | 12M Return: -50.9% | US74276L1052 | Charts, Fundamentals & Technical Analysis

Surgical Robotics, Aquablation Therapy, Urology Systems, BPH Treatment
Total Rating 18
Safety 60
Buy Signal -1.17
Medical Devices
Industry Rotation: -10.1
Market Cap: 1.14B
Avg Turnover: 21.9M
Risk 3d forecast
Volatility57.1%
VaR 5th Pctl9.23%
VaR vs Median-1.85%
Reward TTM
Sharpe Ratio-0.87
Rel. Str. IBD3.3
Rel. Str. Peer Group4.1
Character TTM
Beta0.971
Beta Downside1.469
Hurst Exponent0.433
Drawdowns 3y
Max DD83.22%
CAGR/Max DD-0.19
CAGR/Mean DD-0.43
EPS (Earnings per Share) EPS (Earnings per Share) of PRCT over the last years for every Quarter: "2021-09": -0.32, "2021-12": -0.42, "2022-03": -0.39, "2022-06": -0.43, "2022-09": -0.51, "2022-12": -0.56, "2023-03": -0.63, "2023-06": -0.56, "2023-09": -0.51, "2023-12": -0.54, "2024-03": -0.51, "2024-06": -0.5, "2024-09": -0.4, "2024-12": -0.35, "2025-03": -0.45, "2025-06": -0.35, "2025-09": -0.38, "2025-12": -0.53, "2026-03": -0.56, "2026-06": -0.47,
Last SUE: -0.11
Qual. Beats: 0
Revenue Revenue of PRCT over the last years for every Quarter: 2021-09: 8.668, 2021-12: 10.138, 2022-03: 14.197, 2022-06: 16.691, 2022-09: 20.349, 2022-12: 23.777, 2023-03: 24.404, 2023-06: 33.104, 2023-09: 35.102, 2023-12: 43.581, 2024-03: 44.539, 2024-06: 53.353, 2024-09: 58.37, 2024-12: 68.236, 2025-03: 69.162, 2025-06: 79.182, 2025-09: 83.327, 2025-12: 76.383, 2026-03: 83.132, 2026-06: 94.498,
Rev. CAGR: 47.75%
Rev. Trend: 98.2%
Last SUE: 0.22
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 4.9 years of data

Jan -5.3% 22
Feb -9.8% 47
Mar -7.3% 21
Apr +2.0% 22
May +13.5% 57
Jun -4.3% 22
Jul -6.8% 43
Aug +0.8% 11
Sep -1.6% 37
Oct +4.3% 25
Nov +1.3% 0
Dec +0.5% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: PRCT Procept Biorobotics

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is a surgical robotics company focused on urology, developing, manufacturing, and selling image-guided robotic systems for the treatment of benign prostatic hyperplasia (BPH). Its flagship product, the AquaBeam Robotic System, enables minimally invasive urologic surgery using Aquablation therapy, a heat-free waterjet-based approach that ablates prostate tissue without the thermal risks associated with traditional laser or electrocautery methods. The company also offers the HYDROS Robotic System, which delivers image-guided Aquablation therapy for men suffering from lower urinary tract symptoms (LUTS) caused by BPH.

Founded in 2007 and headquartered in San Jose, California, PROCEPT BioRobotics went public on September 15, 2021, and operates within the Health Care Equipment sub-industry. The company sells its systems in both the United States and international markets, serving a large and growing patient population as BPH is a highly prevalent condition among aging men. Its business model centers on capital equipment sales combined with recurring revenue from procedure-based consumables used during each Aquablation treatment.

Headlines to Watch Out For
  • Aquablation procedure volume accelerates across US hospital systems
  • Gross margin expansion drives path to profitability
  • Hospital capital spending pressure limits new system placements
  • Competition intensifies from alternative BPH treatment options
Piotroski VR-10 (Strict) 1.5
Net Income: -109.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.26 > 0.02 and ΔFCF/TA -8.88 > 1.0
NWC/Revenue: 105.6% < 20% (prev 148.4%; Δ -42.81% < -1%)
CFO/TA -0.23 > 3% & CFO -112.5m > Net Income -109.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.55 > 1.5 & < 3
Outstanding Shares: last quarter (56.5m) vs 12m ago 1.92% < -2%
Gross Margin: 63.74% > 18% (prev 63.61%; Δ 0.13% > 0.5%)
Asset Turnover: 67.98% > 50% (prev 53.59%; Δ 14.39% > 0%)
Interest Coverage Ratio: -30.52 > 6 (EBIT TTM -106.0m / Interest Expense TTM 3.47m)
Altman Z'' 1.24
A: 0.74 (Total Current Assets 420.3m - Total Current Liabilities 64.2m) / Total Assets 479.4m
B: -1.46 (Retained Earnings -700.1m / Total Assets 479.4m)
C: -0.21 (EBIT TTM -106.0m / Avg Total Assets 496.2m)
D: 2.44 (Book Value of Equity 340.1m / Total Liabilities 139.3m)
Altman-Z'' = 1.24 = BB
Beneish M -2.61
DSRI: 1.09 (Receivables 107.6m/80.8m, Revenue 337.3m/274.9m)
GMI: 1.00 (GM 63.61% / 63.74%)
AQI: 1.31 (AQ_t 0.02 / AQ_t-1 0.02)
SGI: 1.23 (Revenue 337.3m / 274.9m)
TATA: 0.01 (NI -109.8m - CFO -112.5m) / TA 479.4m)
Beneish M = -2.61 (Cap -4..+1) = A
What is the price of PRCT shares?

As of September 17, 2026, the stock is trading at USD 19.44 with a total of 1,292,497 shares traded. Over the past week, the price has changed by -6.27%, over one month by -7.82%, over three months by -12.04% and over the past year by -50.87%.

Current recommended Stop Loss: 17.90 (which is 7.9% or 1.3 ATR below the current price).

Is PRCT a buy, sell or hold?

Procept Biorobotics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PRCT.

  • StrongBuy: 6
  • Buy: 1
  • Hold: 4
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the PRCT price?
Analysts Target Price 21.6 11.3%
Procept Biorobotics (PRCT) - Fundamental Data Overview as of 12 September 2026
Market Cap USD = 1.14b (1.14b USD * 1.0 USD.USD)
P/S = 3.3864
P/B = 3.4963
Revenue TTM = 337.3m USD
EBIT TTM = -106.0m USD
EBITDA TTM = -98.9m USD
Long Term Debt = 51.7m USD (from longTermDebt, last quarter)
Short Term Debt = 2.50m USD (from shortTermDebt, last quarter)
Debt = 103.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 25.8m
Net Debt = -124.6m USD (calculated: Debt 103.3m - CCE 227.9m)
Enterprise Value = 1.02b USD (1.14b + Debt 103.3m - CCE 227.9m)
Interest Coverage Ratio = -30.52 (Ebit TTM -106.0m / Interest Expense TTM 3.47m)
EV/FCF = -8.08x (Enterprise Value 1.02b / FCF TTM -126.0m)
FCF Yield = -12.38% (FCF TTM -126.0m / Enterprise Value 1.02b)
FCF Margin = -37.34% (FCF TTM -126.0m / Revenue TTM 337.3m)
Net Margin = -32.54% (Net Income TTM -109.8m / Revenue TTM 337.3m)
Gross Margin = 63.74% ((Revenue TTM 337.3m - Cost of Revenue TTM 122.3m) / Revenue TTM)
Gross Margin QoQ = 66.01% (prev 64.89%)
Tobins Q-Ratio = 2.12 (Enterprise Value 1.02b / Total Assets 479.4m)
Interest Expense / Debt = 3.36% (Interest Expense 3.47m / Debt 103.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -83.7m (EBIT -106.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.55 (Total Current Assets 420.3m / Total Current Liabilities 64.2m)
Debt / Equity = 0.30 (Debt 103.3m / totalStockholderEquity, last quarter 340.1m)
 Debt / EBITDA = 1.26 (negative EBITDA) (Net Debt -124.6m / EBITDA -98.9m)
 Debt / FCF = 0.99 (negative FCF - burning cash) (Net Debt -124.6m / FCF TTM -126.0m)
 Total Stockholder Equity = 358.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.12% (Net Income -109.8m / Total Assets 479.4m)
RoE = -30.62% (Net Income TTM -109.8m / Total Stockholder Equity 358.5m)
RoCE = -25.84% (EBIT -106.0m / Capital Employed (Equity 358.5m + L.T.Debt 51.7m))
 RoIC = -20.89% (negative operating profit) (NOPAT -83.7m / Invested Capital 400.8m)
 WACC = 8.84% (E(1.14b)/V(1.25b) * Re(9.40%) + D(103.3m)/V(1.25b) * Rd(3.36%) * (1-Tc(0.21)))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.88 | Cagr: 4.66%
 [DCF] Fair Price = unknown (Cash Flow -126.0m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.11 | # QB: 0
Revenue Correlation: 98.19 | Revenue CAGR: 47.75% | SUE: 0.22 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.39 | Chg30d=-0.23% | Revisions=-75% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.68 | Chg30d=-0.02% | Revisions=-77% | GrowthEPS=+2.3% | GrowthRev=+28.4%
EPS next Year (2027-12-31): EPS=-1.15 | Chg30d=-0.03% | Revisions=-77% | GrowthEPS=+31.4% | GrowthRev=+20.6%
[Analyst] Revisions Ratio: -91% (up=0, down=29)